Hyperkalemia Is an Underestimated Risk Factor in COPD
Hyperkalemia risk is higher in severe and very severe COPD patients than patients with moderate COPD. Hyperkalemia was also associated with decreasing kidney function, DM, and ACEi use. Serum potassium levels should be monitored regularly in patients with COPD, particularly those with GOLD-3 and 4.
Authors
- Marita Olsson
- Caroline Ann Owen (ORCID: https://orcid.org/0000-0003-4377-3591)
- Ulrika Emerath
- Stefan Sultana (ORCID: https://orcid.org/0000-0001-9767-1481)
- Isobel Anderson (ORCID: https://orcid.org/0009-0009-4426-7966)
- Jukka Mäenpää (ORCID: https://orcid.org/0000-0002-7129-8807)
- Rod Hughes (ORCID: https://orcid.org/0009-0006-1200-5580)
Institutions
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (Netherlands) (NL)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Italy) (IT)
- AstraZeneca (Sweden) (SE)
- National Patient Safety Foundation (US)
Publication Details
- Journal
- International Journal of COPD
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/copd.s490620
- Citations
- 1
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- AstraZeneca
- European Respiratory Society